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RIASSUNTO 
Il carcinoma mammario è uno dei più diffusi nella popolazione 
femminile. L’immunoterapia, basata sull’impiego di anticorpi monoclonali 
diretti contro antigeni cellulari associati a tumore, rappresenta una valida 
strategia per il trattamento selettivo delle cellule neoplastiche. Il recettore 
tirosina chinasico ErbB2, iper-espresso in diversi tipi di carcinoma, tra cui 
quello mammario, è stato considerato uno dei bersagli più promettenti per 
l’immunoterapia. Sebbene Trastuzumab (Herceptin®), l’anticorpo umanizzato 
attualmente in uso clinico per la terapia del carcinoma mammario ErbB2-
positivo sia efficace, può generare fenomeni di resistenza e/o cardiotossicità. 
Un nuovo frammento anticorpale umano (scFv), chiamato Erbicina, è 
stato ottenuto nel nostro laboratorio mediante tecnologia del phage display e 
riconosce un epitopo di ErbB2 diverso da quello di Trastuzumab. Erbicina è 
stato fuso ad una variante della ribonucleasi pancreatica umana (HP-RNasi), 
resistente all’inibitore delle RNasi, in modo da ottenere una immunoRNasi 
(IR) anti-ErbB2 chiamata Erb-HP-DDADD-RNasi. La nuova IR è in grado di 
inibire la crescita di cellule di carcinoma mammario resistenti o scarsamente 
sensibili a Trastuzumab, sia in vitro che in vivo, più efficacemente dell’IR 
parentale, sensibile all’azione dell’inibitore. Inoltre, Erb-HP-DDADD-RNasi 
non mostra effetti cardiotossici nè in vitro su cardiomiociti umani, nè in vivo 
in modelli di topo sottoposti ad ecocardiografia prima e dopo il trattamento 
con la IR. Tuttavia, un’elevata percentuale di carcinomi mammari risulta 
caratterizzata dall’assenza di ErbB2, come quelli tripli negativi (TNBC). 
Pertanto, come nuovo bersaglio per l'immunoterapia del TNBC abbiamo 
considerato la Nucleolina (NCL), una proteina multifunzionale 
selettivamente espressa sulla superficie delle cellule tumorali che regola la 
biogenesi di alcuni microRNA coinvolti nella tumorigenesi e nella 
chemioresistenza. Abbiamo quindi isolato, mediante tecnologia del phage 
display, un scFv umano diretto contro la Nucleolina (NCL), chiamato 4LB5, 
dotato di effetti anti-tumorali selettivi. 
Nel presente progetto di tesi abbiamo prodotto e caratterizzato una 
nuova IR umana ottenuta dalla fusione di 4LB5 con l’HP-RNasi, chiamata 
4LB5-HP-RNasi. Tale IR: I) conserva l'attività enzimatica della RNasi e la 
capacità di legame dell’scFv parentale ad un pannello di cellule di carcinoma 
mammario NCL-positive; II) riduce drasticamente e selettivamente la vitalità 
e la proliferazione delle stesse cellule tumorali, sia in vitro che in vivo; III) 
induce apoptosi e riduce i livelli di miRNA oncogenici, quali il miR-21, il -
221 ed il -222. 
Tali nuovi immunoagenti umani potrebbero dunque rappresentare 
strumenti preziosi per la terapia di carcinomi mammari che non possono 
essere sottoposti a trattamento con Trastuzumab, a causa di fenomeni di 
resistenza, cardiotossicità o mancata espressione del recettore ErbB2. 
  
SUMMARY 
Breast cancer is the most common cancer in women worldwide. A 
new promising anti-cancer therapy involves the use of monoclonal antibodies 
specific for tumor-associated antigens (TAAs). A TAA of interest for breast 
cancer immunotherapy is ErbB2, a tyrosine kinase receptor overexpressed in 
25-30% of breast carcinomas but not on most of normal tissues. 
Trastuzumab, a humanized anti-ErbB2 antibody in clinical use for the 
therapy of breast cancer, is effective but can cause resistance and/or 
cardiotoxicity. Taking advantage of phage display technology, we had 
previously isolated a human anti-ErbB2 scFv, named Erbicin, which 
recognizes an epitope different from that of Trastuzumab. We then 
engineered an anti-ErbB2 immunoRNase (IR), called Erb-HP-DDADD-
RNase, by fusing Erbicin with a human pancreatic RNase (HP-RNase) 
variant, made resistant to the cytosolic RNase inhibitor (RI).  
Here we report that this novel IR is endowed with antiproliferative 
activity for Trastuzumab-resistant breast cancer cells, both in vitro and in 
vivo, that is more potent than that of the parental immunoRNase, which is 
sensitive to the RNase inhibitor. Importantly, Erb-HP-DDADD-RNase does 
not show cardiotoxic effects in vitro on human cardiomyocytes neither 
impairing cardiac function in a mouse model. 
Since, unfortunately, most of human breast tumors as the aggressive 
triple negative breast cancer (TNBC) are ErbB2-negative, we characterized a 
novel target for immunotherapy of TNBC to complement the promising data 
on IR/ErbB: Nucleolin (NCL), a multifunctional protein, selectively 
expressed on the surface of cancer cells, which regulates also the biogenesis 
of specific microRNAs (miRNAs) involved in tumor development and drug-
resistance.  
By using phage display, we have isolated a novel human anti-NCL 
scFv, named 4LB5, endowed with selective anti-tumor effects. Here we 
report on the construction and characterization of a novel immunoRNase 
made up of 4LB5 and human pancreatic RNase (HP-RNase), named 4LB5-
HP-RNase. This novel IR: i) retains both the enzymatic activity of human 
pancreatic RNase and the specific binding of the parental scFv to a panel of 
surface NCL-positive breast cancer cells; ii) dramatically and selectively 
reduces the viability and proliferation of NCL-positive tumor cells, both in 
vitro and in vivo; iii) induces apoptosis and strongly affects the levels of 
tumorigenic miRNAs, such as miR-21, -221 and -222.  
Altogether, these two novel immunoagents could be valuable tools for 
the therapeutic need of breast cancer patients ineligible for Trastuzumab 
treatment due to resistance, cardiotoxicity or lack of ErbB2 receptor.
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INTRODUCTION 
 
 
1. Breast cancer: novel ErbB2-targeted therapies 
 
Breast cancer is the most common cancer in women worldwide with 
nearly 1.7 million new cases diagnosed in 2012. It affects one in eight 
women during their lives (1). 
The treatment for patients with breast cancer is continuously 
evolving. Over the last decade, the introduction of novel antitumor agents 
has led to notable changes in therapeutic strategy, and improvements in 
survival, yet breast cancer remains an increasing public health problem.  
One of the most promising and exciting fields in modern anti-cancer 
therapy involves the use of monoclonal antibodies to target tumor-
associated antigens (TAAs) expressed at high levels on the surface of 
cancer cells but not on their normal counterpart. A large number of 
monoclonal antibody-based therapies is undergoing clinical evaluation or 
has been already approved by FDA and currently in use (2).  
A TAA of interest for breast cancer immunotherapy is ErbB2 
(HER-2/neu), a tyrosine kinase receptor, overexpressed on many 
carcinoma cells of different origin (3-5), which plays a key role in the 
development of malignancy and correlates with a poor prognosis (6).  
Antitumor strategies based upon antibodies have been successfully 
estabilished for ErbB2, leading to the recent clinical approval of 
humanized antibodies and immunoconjugates, such as Pertuzumab and T-
DM1 (7, 8) and to the wide clinical use of Trastuzumab either in early or 
metastatic breast cancer (9, 10). However, the clinical efficacy of these 
drugs is still limited by resistance and cardiotoxicity issues. For instance, 
up to 70% of breast cancer patients are resistant to Trastuzumab and 
large-scale clinical studies have shown that 7 or 28% of patients suffer 
from cardiac dysfunction when Trastuzumab is used alone or in 
combination with anthracyclines, respectively (11-15). The underlying 
mechanism of Trastuzumab cardiotoxicity is based on its capacity to 
inhibit the neuregulin (NRG-1) mediated heterodimerization of 
ErbB2/ErbB4 on cardiac cells, thus interfering with the pathways of 
myocyte survival, induced by ErbB2 (16). ErbB2 is indeed the 
preferential heterodimerization partner for the other members of EGFR 
family. 
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Fig. 1 - Tyrosine-kinase receptors (TKRs) of the EGFR family and 
ErbB2 signaling pathways. 
 
 
Epidermal growth factor receptor–ligand interaction induces the 
heterodimerization of ErbB receptors, which in turn results in the 
activation of intracellular tyrosine kinase domain and downstream 
signaling cascades that mediate cell growth, differentiation, and survival 
(17-19) such as mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI3K) pathways (Figure 1).  
The ErbB2 receptor lacks nature ligands and differently from the 
other ErbB receptors is already in an open conformation which can 
interact with the other members of the family, thus its overexpression in 
cancer cells induce dimerization and initiates signal transduction 
activating dysregulated proliferation. 
Another obstacle to the success of present-day immunotherapy is 
represented by the immune responses against the nonhuman components. 
In fact an ideal anticancer drug should not only selectively target tumor 
cells, but it should also be nonimmunogenic.  
In order to overcome these limits fully human immunoagents, 
obtained by phage display technology (20), capable of inhibiting tumor 
growth, would meet all these requisites, and provide safe and highly 
selective antitumor drugs. 
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The phage display methodology allows for the isolation of fully 
human antibody fragments, which are the minimal portions of an antibody 
still capable of binding to the target antigen (Figure 2). A single chain 
variable fragment (scFv) is made up of the variable domains of the heavy 
(VH) and light chain (VL) connected by a flexible oligopeptide. This 
fragment retains the binding specificity for the antigen but is able to 
diffuse more easily into the tumor masses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 - Schematic representation of the phage display technology. 
 
These scFvs can be conjugated with radionuclides or toxins derived 
from plants or bacteria (21, 22), thus combining the potent toxicity of 
these molecules with the antigen specificity of the antibodies (23, 24) for 
an efficient killing of target cells.  
However, these immunoconjugates, called “immonotoxins”, could 
be immunogenic and can induce non-specific toxicities, such as vascular 
leak syndrome and hepatotoxicity, thus limiting the therapeutic potential 
of these immunoconjugates (25, 26). 
To circumvent these problems, the toxin has been replaced by a 
non-immunogenic and non-toxic ribonuclease, such as ribonuclease 1 or 
human pancreatic ribonuclease.  
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The novel human antitumor immunoconjugate, named 
immunoRNase (IR), was engineered in our laboratory by isolation 
through phage display technology of a novel human antibody fragment 
anti-ErbB2, named Erbicin (27), and its genetic fusion with a human 
pancreatic ribonuclease (HP-RNase) (Figure 3) (28). Erbicin binds to 
ErbB2 receptor and is internalized by the cells through receptor-mediated 
endocytosis, thus allowing for the RNase to enter the cells and act as a 
toxin only for target cells by exerting its enzymatic activity on cellular 
RNAs (28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 - Schematic representation of the immunoRNase (IR). 
 
 
This first-generation anti-ErbB2 immunoRNase (Erb–HP-RNase) 
binds selectively and with high affinity to ErbB2-positive cells, and 
specifically inhibits their proliferation both in vitro and in vivo (28-30).  
Furthermore, Erb–HP-RNase does not show cardiotoxic side effects 
either in vitro or in vivo probably because Erbicin binds to an epitope 
different from that of Trastuzumab (31, 32).  
Unexpectedly, however, Erb–HP-RNase was found to be at least 
partially sensitive to the neutralizing action of the RNase inhibitor (RI), a 
cytosolic protein with a high affinity for HP-RNase (33-35).  
Based on the concern that the fraction of Erb–HP-RNase 
sequestered by the cytosolic inhibitor could not exert its antitumor 
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activity, we engineered a second-generation immunoRNase, named Erb–
HP-DDADD-RNase, by fusing Erbicin with a variant of HP-RNase made 
resistant to RI. In this variant, five residues of the ribonuclease at the RI–
HP-RNase interface are replaced (R39D/N67D/N88A/G89D/R91D) in 
order to reduce the affinity for RI but still retaining high RNA-degrading 
activity (35) (Figure 4). Erb–HP-DDADD-RNase has been found to be 
fully resistant to RI inhibition and kill mammary ErbB2-positive tumor 
cells more efficiently than Erb–HP-RNase (36).  
Fig. 4 - The variant HP-RNase (HP-DDADD-RNase) and its 
interaction with the ribonuclease inhibitor (RI). A: The five residues 
replaced in the pancreatic ribonuclease. B: The complex of RI and HP-
RNase. 
 
Here we report on the antitumor properties of Erb–HP-DDADD-
RNase on Trastuzumab-resistant breast cancer cells and its eventual 
cardiotoxic effects, tested both in vitro and in vivo, to reveal its 
therapeutic potential for cancer patients that suffer from cardiac 
dysfunction and/or are ineligible for Trastuzumab treatment due to natural 
or acquired resistance. 
 
2. A novel approach for triple-negative breast cancer (TNBC) therapy  
 
Unfortunately, a high fraction of breast tumors do not express 
ErbB2. Since ErbB2 overexpression/amplification occurs only in ~25% of 
human breast cancer patients (4), new targets have been investigated for 
the other untreatable breast tumors, such as triple-negative breast cancer 
(TNBC).  
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TNBC is indeed characterized by the absence of estrogen receptor 
(ER), progesterone receptor (PR) and ErbB2, thus excluding the 
possibility of using efficacious targeted therapies developed against these 
proteins. TNBC accounts for ~14% of all breast cancers and 
approximately 170,000 patients worldwide are diagnosed annually with 
TNBC (37). These patients show high risk of recurrence and visceral 
metastasis and their death rate is disproportionately higher than any other 
subtype of breast cancer (median overall survival around 12 months in the 
metastatic setting) (38).  
A new attractive target for triple-negative breast cancer 
immunotherapy is today represented by Nucleolin (NCL), a major 
nucleolar protein of exponentially growing eukaryotic cells (39), which is 
directly involved in the ribosomal processing (40, 41). Nucleolin 
represents a particularly important multi-functional protein which plays a 
key role in DNA and RNA metabolism, chromatin structure, rDNA 
transcription, rRNA maturation and ribosome biogenesis; it also functions 
as a cell surface receptor, where it acts as a shuttling protein between 
cytoplasm and nucleus, and thus it can even provide a mechanism for 
extracellular regulation of nuclear events (42, 43) (Figure 5).  
Although NCL is predominantly localized in the nucleus, a large 
number of reports have shown enhanced expression of cytoplasmic and 
surface NCL in many different tumor cell types such as leukemic (44), 
renal (45), pulmonary (46), prostate (47), intestinal (48, 49), breast (46, 
50, 51), hepatic (52), kidney (53), cervical (46, 54) and colon (46, 55) 
cancer cells, melanomas (46, 56) and gliomas (57, 58).  
Altered NCL surface expression and localization is directly or 
indirectly involved in signal transduction events subsequently to its 
interaction with several molecules/receptors on the cell surface that are all 
known to be involved in tumor cell growth, invasiveness, inflammation 
and/or angiogenesis. In line with its role in RNA processing, recent 
published studies (41) report that NCL also promotes the maturation of a 
specific set of microRNAs (miRNAs), such as miR-21, -221 and -222, 
whose up-regulation is involved in breast tumorigenesis, metastasis 
formation, and drug resistance (59-62). 
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Fig. 5 - A schematic representation of the biological functions of 
Nucleolin in eukaryotic cells. a) chromatin condensation and 
decondensation; b) Nucleolin and pre-RNA; c) maturation of 48S rRNA; 
d) cell surface functions; e) expression of Nucleolin in small secretory 
vesicles; f) shuttling activities: Nucleolin acts as a shuttling protein to 
carry ribosomal protein from cytoplasm to nucleus during the assembly of 
ribosomes; g) export activities: Nucleolin might be involved in exporting 
the assembled ribosomes from nucleus to cytoplasm; h) cell death and 
apoptosis.  
 
NCL targeting affects breast cancer aggressiveness through miRNA 
regulation as NCL could mediate their transfer to the cytosol, to cell 
membrane and to the extracellular microenviroment, thus regulating their 
oncogenic effects. Indeed, the cells release a significant number of RNA-
binding proteins into the culture medium, such as Nucleolin and 
Nucleophosmin 1 (NPM1), which can protect miRNA from degradation, 
thus suggesting that these proteins may play a role in the exportation, 
packaging and protection of extracellular miRNAs (63). 
Recently, the release from tumor cells of extracellular vescicles 
(EVs) has become the subject of increasing interest for its role in cancer 
intercellular communication. The EVs are spherical structures made up of 
a lipid bilayer that contain proteins, genetic material and bioactive lipids 
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(64, 65) derived from the cytosol of the donor cells, thus the cargo 
represents the information released by one cell to a recipient cell. The 
EVs include exosomes (50-100 nm) secreted from the endosomal 
membrane compartment after the fusion of multivesicular bodies with the 
plasma membrane, and microvesicles (100 nm-1 mm), which bud directly 
from the plasma membrane (64). However, numerous similarities exist in 
terms of physical characteristics and compositions of exosomes and 
microvesicles, thus making challenging the exclusive purification of the 
target vesicles after their secretion from cells (66, 67).  
A key component of the EVs-associated cargo is represented by 
miRNAs which can be delivered to another cell, and thus can display their 
oncogenic role (65).  
Altogether these observations support the importance of 
tumorigenic miRNAs in immune escape, neovascularization and 
metastasis and the key role of NCL to affect their levels. 
Thus surface NCL has become an attractive target for cancer 
therapy even because is continuously and abundantly expressed on the 
tumor cell surface compared with normal cells and is associated with the 
proliferative capacity of cells independently from nuclear NCL (68).  
Several groups have attempted to develop molecules, such as 
aptamers (AS1411) or peptides (HB-19, V3 loop-mimicking 
pseudopeptide, N6L, and F3) (69-72), to bind and to inhibit NCL in 
cancer cells. These compounds have also been suggested as potential 
carriers for the targeted delivery into cancer cells of several antineoplastic 
agents. Although promising, aptamers and peptides targeting NCL suffer 
from intrinsic limitations, such as extremely short half-life, undesired 
immunostimulatory actions, and still unknown toxicological effects (73). 
To circumvent these problems, in our laboratory, in collaboration 
with a research group of the Ohio State University, a novel fully human 
anti-NCL scFv, named 4LB5, has been isolated by phage-display 
technology (Figure 6) (74). This immunoagent recognizes with high 
affinity the RNA binding domain (RBD) of NCL, selectively binds to 
NCL on the cell surface and discriminates between cancer and normal-
like breast cells (Figure 7). 4LB5 is also internalized into the cytoplasm of 
target cells, reduces their cell viability and proliferation both in vitro and 
in vivo, and abrogates the biogenesis of NCL-dependent miRNAs (74).  
To enhance the potential therapeutic effect of 4LB5 we have 
engineered an anti-NCL novel fully human immunoRNase, named 4LB5-
HP-RNase, by fusing 4LB5 with the human pancreatic ribonuclease in a 
similar manner to the previously described anti-ErbB2 IR (28). 
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Here we describe the production and characterization of this novel 
IR and we report on its antitumor effects both in vitro and in vivo. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 - ELISA binding assay to NCL of novel fully human anti-NCL 
scFvs obtained by phage display and identification of 4LB5 as the 
best binder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 - Characterization of anti-NCL scFv 4LB5 on breast cancer 
cells. A: Binding assays of 4LB5 to NCL-positive triple-negative breast 
cancer MDA-MB-231 cells or to NCL-negative breast normal-like MCF-
10a cells. B: Internalization of Cy5 labelled 4LB5 by MDA-MB-231 
cells.
                                                                                                           Materials and Methods 
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MATERIALS AND METHODS 
 
1. Cell cultures 
The human breast cancer SKBR3, MDA-MB-436 and BT549, the 
colorectal adenocarcinoma SW-620, and the human epidermoid 
carcinoma A431 cell lines were cultured in RPMI 1640 (Gibco BRL, Life 
Technologies, Paisley, UK). The JIMT-1 cell line, established from a 
pleural metastasis of a 62-year-old breast cancer patient resistant to 
Trastuzumab, and the triple-negative breast cancer MDA-MB-231 cell 
line were grown in Dulbecco's modified Eagle's medium (Gibco BRL). 
The human breast cancer MCF-7 cell line was grown in Eagle’s 
Minimum Essential Medium (MEM, Gibco BRL).  
Media were supplemented with 10% (vol/vol) heat-inactivated fetal 
bovine serum (7.5% for JIMT-1), penicillin (100 UI ml
–1
), streptomycin 
(100 µg ml
–1
) and 2 mM glutamine (all from Gibco BRL) in a humidified 
atmosphere of 95% air and 5% CO2 at 37°C. 
The normal-like breast MCF10a cell line was cultured in Mammary 
Epithelial Cell Growth Medium (MEGM, Lonza, Basel, CH) 
supplemented with 10% FBS, bovine pituitary extract, hydrocortisone, 
hEGF, insulin (BulletKit, Lonza) and 100 ng/ml cholera toxin. 
All cell lines were purchased from the American Type Culture 
Collection (ATCC). 
 
2. Antibodies 
The following antibodies were used: horseradish peroxidase (HRP)-
conjugated anti-penta-His mouse monoclonal antibody (Qiagen GmnH, 
Hilden, Germany), affinity-isolated IgGs from a rabbit anti-HP-RNase 
antiserum (Igtech, Salerno, Italy), anti-NCL mouse monoclonal antibody 
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-PARP rabbit 
polyclonal antibody,  anti-ErbB2 rabbit monoclonal antibody (Cell 
Signaling Technology, Danvers, MA, USA), anti-actin rabbit polyclonal 
antibody (Sigma-Aldrich, St Louis, MO, USA), HRP-conjugated anti-
rabbit immunoglobulins from goat antiserum, HRP-conjugated anti-
mouse immunoglobulins from goat antiserum (Thermo Scientific, 
Rockford, IL, USA). 
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3. Bacterial strains 
 The E. coli DH5α (Invitrogen, Life Technology, Inc., Paisley, 
UK) and BL21 DE3 (Novagen-Merk Millipore, Darmstadt, Germany) 
strains were used for cDNA amplification and expression of the 
immunoRNases, respectively. 
 
4. Bacterial culture medium 
LB (Luria-Bertani) culture medium was used for the growth of 
bacteria and prepared as described by Sambrook et al. (75). To transform 
the E. coli BL21 DE3 competent cells, 50 µg/ml ampicillin (Applichem 
GmbH, Darmstadt, Germany) was added to the medium. 
 
5. Bacterial transformation 
The BL21 DE3 competent cells (200 µl) were transformed with 50 
ng plasmid DNA and incubated on ice for 40 min. The cells were 
subjected to heat shock at 42°C for 2 min and then incubated at 37°C for 
1 hour after addition of 800 µl LB medium. Aliquots of each mixture (200 
µl) were seeded on LB-agar plates containing 100 µg/ml ampicillin, 
which were then incubated at 37°C for 16 h. 
 
6. Generation, expression and purification of 4LB5–HP-RNase  
The cDNA encoding the human pancreatic RNase was cloned into 
the T7 promoter-based E. coli pET22b+ expression vector downstream to 
the sequence encoding the available human 4LB5 scFv. A spacer was 
included between the two cDNAs to minimize the steric hindrance 
between the two moieties of the chimeric protein, as previously described 
(36). The recombinant plasmid was fully sequenced to confirm the 
expected DNA sequence.  
Cultures of Escherichia coli BL21 DE3 (Novagen, Merk Millipore, 
Darmstadt, Germany), previously transformed with the recombinant 
pET22b+ expression vector containing the cDNA of 4LB5-HP-RNase, 
were grown at 37°C in Luria–Bertani (LB) medium containing 50 µg/ml 
ampicillin until the exponential phase was reached. The expression of IR 
was induced by addition of 1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG; Applichem GmbH, Darmstadt, Germany) in the cell culture, 
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which then was grown at room temperature for 4 h. The cells were 
harvested by centrifugation at 6000 rpm for 15 min at 4°C.  
Recombinant protein was extracted from the insoluble fraction of 
pET22b(+)-4LB5-HP-RNase-transformed BL21 (DE3) bacterial cells. To 
this aim, the fraction was solubilized in a PBS buffer containing 7 M 
UREA and incubated by slowly rotating overnight at 4°C in the presence 
of EDTA-free protease inhibitors (Roche Applied Science GmbH, 
Manheim, Germany). After centrifugation at 28000 g for 20 min at 4°C 
the supernatant was incubated with a 100% saturated solution (4M) of 
ammonium sulfate, added drop-wise at 4°C, to allow for the protein 
precipitation. The mixture was incubated for 1 hour at 4°C while slowly 
stirring and then centrifuged at 28000 g for 10 min at 4°C. The 
precipitated material was resolubilized in resin binding buffer (20 mM 
sodium phosphate, 0,5 M NaCl, 10 mM imidazole pH 7.4) in the presence 
of 4 M UREA and EDTA-free protease inhibitors, and incubated for 
further 18 h at 4°C while slowly stirring. After centrifugation at 28000 g 
for 10 min at 4°C in order to remove unsoluble proteins, the cleared 
supernatant was loaded on an immobilized-metal affinity chromatography 
(IMAC) by incubation with cobalt-chelating resin (TALON
®
; Clontech, 
Palo Alto, CA, USA) overnight at 4°C by gentle rotation. After extensive 
washes in an appropriate buffer (20 mM sodium phosphate, 0,5 M NaCl, 
20 mM imidazole) by decreasing urea concentration in 10% glycerol 
(vol/vol), the elution step was performed with the same buffer containing 
a higher concentration of imidazole (250 mM).  
The “BCA Protein Assay” kit (Pierce, Thermo Fisher Scientific) 
was used to measure the concentration of the purified protein according to 
the manufacturer’s recommendations. Briefly, the samples were incubated 
with BCA at 60°C for 30 min and the absorbance was measured 
spectrophotometrically at 562 nm. All measurements were performed in 
duplicate. 
 
7. Western blotting analyses 
The purity of the final preparation was evaluated by SDS-PAGE as 
described by Laemmli (76). At the end of the electrophoretic run, 
performed at 150 V, the gel was treated as follows: 
a) Coomassie staining: the gel was stained in a Coomassie blue solution 
(20% isopropanol, 10% acetic acid; 0,1% Coomassie blue) by 
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incubation for 30 min under gentle shaking. The gel was destained 
with extensive washes in a solution containing 20% ethanol and 7% 
acetic acid. 
b) Western blotting analyses: the proteins were transferred by 
electroblotting (25 V) onto a PVDF membrane at 4°C for 16 h. The 
membrane was incubated in 10 ml of blocking solution (1X PBS, 0,1% 
Tween 20, 5% BSA) at 25°C for 1 h and then incubated with 
appropriate dilutions of a peroxidase-conjugated anti-His antibody in 
PBS containing 0,1% Tween and 1% BSA at 25°C for 90 min. After 
extensive washes in a PBS solution containing 0,1% Tween 20, the 
bands were detected by chemiluminescence with a phoshorimager  
(45–710; Bio-Rad, Hercules, CA, USA). 
 
8. RNase activity  
RNase zymograms, carried out by SDS-PAGE electropherograms, 
were performed as previously described (77).  
Briefly, the gel was incubated in a buffer of 50 mM Tris-HCl pH 
7.4 containing 25% isopropanol solution for 30 minutes to increase the 
sensitivity of the signal detection. The gel was equilibrated in 50 mM 
Tris-HCl pH 7.4 for 30 minutes and then incubated in the same solution 
containing 4 mg/ml yeast RNA (Sigma-Aldrich) at 37°C for 10 min. The 
gel was washed out with 50 mM Tris-HCl pH 7.4 and stained in a 
solution of 0,2% toluidine blu containing 0,1% acetic acid solution for 15 
minutes at room temperature by gentle agitation. Finally, the gel was 
destained by extensive washes in water.  
Erb-HP-RNase was used as positive control in a parallel assay. 
 
9. Cell ELISA assays 
Binding assays were performed by modified enzyme-linked 
immunosorbent assay (ELISA), as previously described (28). ELISA 
assays for 4LB5-HP-RNase or 4LB5 were performed on surface NCL-
positive MDA-MB-231, MDA-MB-436, BT549 or MCF-7 breast cancer 
cells and surface NCL-negative MCF10a normal-like breast cells. 
 Briefly, all the cells were harvested in non-enzymatic dissociation 
solution (Sigma-Aldrich), washed and transferred to U-bottom microtiter 
plates (2 × 10
5
 cells per well). After blocking with PBS containing 6% 
bovine serum albumin (BSA), the cells were incubated in the absence or 
in the presence of increasing concentrations of IR in ELISA buffer 
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(PBS/BSA 3%) for 90 min at 25°C by gentle shaking. After 
centrifugation at 1200 rpm for 7 min and the removal of supernatant, cell 
pellets were washed twice in 200 µl of PBS buffer, resuspended in 100 µl 
of ELISA buffer and incubated for 1 h with a peroxidase-conjugated anti-
His antibody. After 1 h, the plates were centrifuged, washed with PBS 
buffer and reacted with 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich). 
The enzymatic reaction was stopped with 1 N HCl, and the binding values 
were determined from the absorbance at 450 nm and reported as the mean 
of three determinations. The SD (≤5%) was calculated on the basis of the 
results obtained in three independent experiments. 
To further confirm that the observed binding was due to the specific 
interaction between 4LB5 and NCL on cell surface, the binding of 4LB5-
HP-RNase to MDA-MB-231 cells was analyzed by ELISA assay before 
and after its pre-incubation with equimolar doses (50 nM) of NCL-RBD 
(RNA Binding Domain) recombinant protein. To this aim IR was pre-
incubated for 2 hours at 4°C with NCL-RBD recombinant protein by 
gentle rotation and then tested on MDA-MB-231 cells as described above. 
 
10. Pull-down assay 
Pull-down experiments were performed to determine the specific 
interaction between 4LB5 or 4LB5-HP-RNase and cellular NCL. 
With this aim subconfluent MDA-MB-231 cells were harvested and 
lysed. Whole-cell extracts (WCE) were obtaining by using NTEN lysis 
buffer (150 mM NaCl, 0.2 mM EDTA, 50 mM Tris-HCl at pH 7.5, 1% 
[vol/vol] NP-40) containing protease inhibitors. The “BCA Protein 
Assay” kit (Pierce, Thermo Fisher Scientific) was used to measure the 
concentration of the WCEs. An aliquot of 2 mg of total protein extracts 
was incubated with equimolar doses (100 nM) of 4LB5 or 4LB5-HP-
RNase, or with control buffer (PBS) and loaded on Ni-NTA Magnetic 
Agarose Beads (Qiagen) for 2 h at room temperature by continuous 
stirring to allow for the capture of the chimeric proteins by their His-tag.  
The resin was washed out four times with 1 ml of NTEN lysis 
buffer containing 0.25% NP-40. The samples were boiled in 2× SDS 
sample buffer, run on SDS-PAGE gel, transferred to PVDF and probed 
with appropriate dilutions of anti-NCL or anti-His antibodies. 
 
11. Confocal microscopy  
Internalization of 4LB5-HP-RNase was assessed by confocal 
microscopy. 4LB5 and 4LB5-HP-RNase were Cy5-labeled using LYNX 
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Rapid Cy5 antibody conjugation kit (AbD Serotec), according to the 
manufacturer instructions. Sub-confluent MDA-MB-231 cells were 
seeded over a glass multi-well, treated with 1 g/mL of Cy5-4LB5 or 
Cy5-4LB5-HP-RNase diluted in complete medium and cultured at 37 °C 
for 4 h to allow for their internalization. Cells were extensively washed 
with PBS and complete medium (without Cy5-labeled antibodies) was 
replaced, following the addition of Hoechst dye for nuclear staining. Live 
cell images were acquired using an Eclipse Ti-E microscope (Nikon), and 
z-stacks were also acquired to obtain 3D-images and further confirm 
internalization. Laser conditions for fluorescence acquisition were kept 
constant in all the experimental points. Images were processed using the 
NIS-Elements software (Nikon). 
 
12. In vitro cytotoxicity assays 
Cells were seeded in 96-well flat-bottom plates; SKBR3 cells at a 
density of 1.5 × 10
4
 per well; A431 and JIMT-1 cells at a density of 5 × 
10
3
 per well. To test the effects of Erb–HP-RNase or Erb–HP-DDADD-
RNase on cell growth, SKBR3 and A431 cells were incubated at 37°C for 
72 h with the IRs (10–100 nM) in the culture medium. 
JIMT-1 cells were deprived of serum for 24 h and then treated with 
the IRs (10–100 nM) for 72 h in medium containing 0.1% serum. Cell 
counts were determined in triplicate by using the trypan blue exclusion 
test by an Automated Cell Counter TC10 (Bio-Rad, Richmond, CA, 
USA). Cell survival was expressed as a percentage of viable cells in the 
presence of the tested proteins, with respect to untreated control cultures. 
The SD (≤5%) was calculated on the basis of the results obtained in three 
independent experiments. 
 
MDA-MB-231 and MDA-MB-436 cells were plated in 96-well 
plates at a density of 7 × 10
3
 per well; BT-549, MCF-7 and MCF10a cells 
at density of 1 x 10
4
 per well. Cells were treated with the increasing 
concentrations (10-100 nM) of 4LB5-HP-RNase and incubated at 37°C 
for 72 h. Cells counts were performed by Trypan blue excluding test. The 
cell survival is reported as percentage of viable cells in the presence of the 
protein under test with respect to control untreated cells. 
 
In vitro cardiotoxicity assays were performed with human fetal 
cardiomyocytes (HFCs) as previously described (16). Briefly, to test the 
cardiotoxicity of Erb-HP-DDADD-RNase, HFC cells were seeded in 96-
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well microtiter plates at a density of 1 x 10
4
 cells/well, and allowed to 
adhere overnight. After 16 h at 37°C, the medium was replaced with 
medium containing Erb-HP-RNase, Erb-HP-DDADD-RNase (each at 
concentration of 50 or 100 nM), or Doxorubicin (0.1 or 0.25 uM), used as 
a positive control. After the treatment carried out for 72 h at 37°C, cells 
were washed with PBS and stained with trypan blue or tested by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay for the 
determination of cell survival, as previously described (16). Cell survival 
was expressed as percent of viable cells in the presence of the drug under 
test with respect to control cultures grown in the absence of the drug.  
Typically, cell survival values were obtained from at least three 
independent experiments in which five determinations were performed 
for each sample. Standard deviations were calculated on the basis of the 
results obtained from all the experiments. 
 
13. Colony Assays 
For colony assay experiments, MDA-MB-231, MDA-MB-436 or 
BT-549 cells (200 cells/well) were plated in 12-well plates and treated 
with 100 nM 4LB5-HP-RNase or 4LB5 in complete medium for 72 h. 
Then, cells were replenished with complete medium without chimeric 
proteins and allowed to grow for 7 additional days, to allow for the 
formation of the colonies. Cells were then fixed with 1% glutaraldehyde 
in PBS, stained with Crystal violet and counted. 
 
14. Cellular internalization analyses 
ErbB2-positive SKBR3 cells and JIMT1 cells resistant to 
Trastuzumab were seeded in 6-well flat-bottom plates at a density of 6 × 
10
5
/well and grown at 37°C for 24 h in culture medium. After the addition 
of an immunoRNase at a concentration of 200 nM, cells were incubated 
for 2 h at 37°C. Cells were then washed extensively with a stripping 
solution of 50 mM glycine buffer, pH 3.0, containing NaCl (1.0 M), 
harvested with dissociation solution and lysed as previously described 
(78). Internalized Erb–HP-RNase or Erb–HP-DDADD-RNase was 
detected by Western blotting of cell extracts by using appropriate 
dilutions of the anti-HP-RNase antibody, followed by an HRP-conjugated 
anti-rabbit antibody. The signal intensity of the reactive bands was 
measured with a phosphorimager (45–710; Bio-Rad, Hercules, CA, 
USA). 
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15. Purification of extracellular vesicles (EVs) 
For EVs purification SW620 cells at 80-90% confluency were 
washed twice with phosphate-buffered saline (PBS) and then incubated in 
serum-free RPMI-1640 for 24 h to avoid potential contamination from 
serum-derived vesicles and proteins.  
Approximately 80 mL of conditioned medium were collected and 
cells/cell debris were removed from the cell culture supernatant by using 
a combination of differential centrifugation, as follows: 50 g for 20 min, 
100 g for 20 min, 300 g for 10 min, 2000 g for 20 min and 2000 g for 45 
min.  The cell culture supernatant was recovered and further clarified by 
filtration through 0.22 μm filter (Millipore).  
EVs were isolated by adding ExoQuick
TM
 exosome precipitation 
reagent according to manufacturer's reccomendations and incubated 
overnight at 4°C to allow for the EVs precipitation. The 
ExoQuick/supernatant mixture was centrifuged at 1500 g for 30 min and 
the supernatant was removed.  
The EVs pellet was resuspended in a sterile nuclease-free PBS 
solution and incubated with equimolar doses of 4LB5 or 4LB5-HP-RNase 
(50 nM) at 37°C for 2 h or with a PBS control solution. 
 
16. RNA extraction 
The RNA extraction was performed by using “RNA clean-up and 
concentration” micro kit (Norgen) according to the manufacturer’s 
instructions. Briefly, total RNA was isolated by using a phenol/guanidine-
based reagent such as Trizol. After the separation of the aqueous and 
organic phases, the upper fraction containing the RNA was collected into 
an RNase-free microcentrifuge tube. One volume of 70% ethanol was 
added to the sample which was then mixed by vortexing. The 
RNA/ethanol mixture was applied onto an RNA-binding column and 
centrifuged at 14000 g for 1 min. The flowthrough was discarded and the 
column was washed three times with the appropriate provided wash 
solution by spinning the sample at 14000 g for 1 min. The purified RNA 
was eluted in RNase-free water in a final volume of 50 μl. The RNA 
concentration was measured spectrophotometrically at 260 nm.   
 
17. Quantitative Real-Time PCRs 
Quantitative real-time PCRs (qRT-PCRs) were performed by using 
the TaqMan Fast-PCR kit (Applied Biosystems) according to the 
                                                                                                           Materials and Methods 
18 
 
manufacturer’s instructions, using the appropriate TaqMan probes for 
miRNA quantification, followed by detection with the 7900HT Sequence 
Detection System (Applied Biosystems). All reactions were performed in 
triplicate. Simultaneous quantification of GAPDH was used as reference 
for intracellular miRNA quantification. Simultaneous quantification of 
RNU48 was used as negative control to evaluate the potential 
contamination of cellular RNAs during the EVs purification procedure. 
The comparative cycle threshold (Ct) method for relative quantification of 
gene and miRNA expression (User Bulletin #2; Applied Biosystems) was 
used to determine miRNA expression levels. 
 
18. In vivo antitumor assays 
The in vivo antitumor activity of Erb–HP-DDADD-RNase was 
determined in Balb/cAnNCrlBR athymic (nu/nu) mice (Charles River 
Laboratories, Calco, Italy). Trastuzumab resistant JIMT-1 cells were 
suspended in sterile PBS and injected subcutaneously into mice at a 
density of 2 × 10
6
 cells/mouse (Day 0). On Day 30, when tumors were 
clearly detectable, Erb–HP-RNase or Erb–HP-DDADD-RNase was 
administered intraperitoneally five times at 72-h intervals to groups of 5 
mice at doses of 1.2 mg kg
–1
 of body weight. Another group of control 
mice was treated with identical volumes of sterile PBS to monitor tumor 
development. Tumor volume (V) was calculated by the formula of a 
rotational ellipsoid: V = A × B
2
, where A is the axial diameter and B is the 
rotational diameter as measured with a caliper. 
To test the in vivo activity of 4LB5-HP-RNase, 2 × 10
6
 viable Luc+ 
MDA-MB-231 cells were injected into the fourth left-side mammary fat 
pad of female NOD-SCID mice (NOD/ShiLtSz; Charles River). Three 
days or 2 weeks after tumor cell inoculation, mice were treated twice a 
week with intraperitoneal injections of 4LB5, 4LB5-HP-RNase (each 2 
mg/kg) or control buffer (PBS). Tumor size was assessed every 7 days by 
bioluminescence imaging, as follows. Briefly, mice were injected with 75 
mg/kg Luciferin (Xenogen), and tumor growth was detected by 
bioluminescence at 20 min after the injection. The homebuilt 
bioluminescence system used an electron multiplying charge-coupled 
device (IVIS-200, Perkin-Elmer) with an exposure time of 30 s and an 
electron multiplication gain of 500 voltage gain × 200, 5-by-5 binning, 
and with background subtraction. After 4 wk of treatment, mice were 
analyzed by bioluminescence images and then sacrificed. The tumor size 
was measured by using a caliper, and the volume was calculated by using 
the formula L × W × H. 
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19. In vivo cardiotoxicity assays 
Cardiac function in vivo was assessed by transthoracic 
echocardiography in sedated 7-week-old WT C57Bl/6 mice (Harlan Italy, 
San Piero al Natisone, UD, Italy) by using a Vevo 2100 high-resolution 
imaging system (40-MHz transducer, VisualSonics, Toronto, ON, 
Canada). Cardiac function was evaluated by non-invasive 
echocardiography in basal conditions and after intraperitoneal treatment 
with five doses (1.2 mg kg
–1
 of body weight) of the novel immunoRNase 
Erb-HP-DDADD-RNase. 
Fractional shortening (FS) and radial strain (RS) were evaluated as 
described previously (16); ejection fraction (%EF) was calculated with 
the formula: %EF = (VTD−VTS/VTD) × 100. Data were the mean ± SD. 
The experiments with mice described herein were conducted in 
accordance with the Italian regulation for experimentation on animals. All 
experiments in vivo were carried out after ethical committee approval and 
met the standards required by the Directive 2010/63/EU of the European 
Parliament.
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RESULTS 
 
1. Breast cancer: ErbB2-targeted therapies 
 
1.1.  In vitro cytotoxic effects on breast tumor cells and 
internalization of Erb-HP-DDADD-RNase  
 
The novel immunoRNase Erb–HP-DDADD-RNase was tested for 
its cytotoxic effects on ErbB2-positive and ErbB2-negative tumor 
cells. The cells were plated in the absence or in the presence of increasing 
concentrations of the IRs, Erb–HP-RNase or Erb–HP-DDADD-RNase. 
After 72 h of incubation at 37°C, cell survival was measured by counting 
trypan blue-excluding cells. As shown in Figure 8A, Erb–HP-DDADD-
RNase was found to be selectively cytotoxic in a dose-dependent manner 
on the ErbB2-positive SKBR3 and Trastuzumab-resistant JIMT-1 breast 
cancer cell lines tested, whereas no effects on ErbB2-negative A431 
epidermoid cancer cells, used as control, were observed. Surprisingly, 
despite the different sensitivity to ribonuclease inhibitor (RI) of the two 
IRs, no different effects on cell survival were detected when Erb–HP-
RNase or Erb–HP-DDADD-RNase were tested on SKBR3 cells 
expressing high levels of ErbB2, whereas a stronger cytotoxicity of Erb–
HP-DDADD-RNase with respect to that of ERBrb–HP-RNase was 
evidenced on JIMT-1 cell line, particularly when low protein 
concentrations were used (79).  
The different efficacy of the two immunoRNases is consistent with 
the hypothesis that increased levels of ErbB2 receptor lead to increased 
internalization. To investigate whether SKBR3 and JIMT-1 cells express 
different level of ErbB2 on their surface, a quantitative analysis was 
performed on their lysates by western blotting with a commercial anti-
ErbB2 mAb (Figure 8B). The positive bands were analyzed with a 
phosphorimager, and the corresponding signal intensities were 
normalized to those obtained in the same lysates by an anti-actin 
antibody. Indeed, SKBR3 cells were found to express higher levels of 
ErbB2 with respect to JIMT-1, as expected.  
Thus, SKBR3 cells expressing high levels of ErbB2 receptor allow 
for the internalization of large amounts of the immunoRNases that exceed 
the quantity of endogeneous RI, leading to the inhibition of only a small 
fraction of each immunoRNase (80). In contrast, lower levels of ErbB2 
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such as those detected in JIMT-1 cells allow for less efficient 
internalization of the immunoRNases, leading to a different behavior. 
In these cells, Erb–HP-RNase is efficiently inhibited by RI and 
manifests poor cytotoxic activity, whereas the RI-resistant Erb–HP-
DDADD-RNase can fully exert its activity. 
Fig. 8 - In vitro effects of the IRs on tumor cell survival.  
A: Dose–response curves of ErbB2-positive SKBR3 (triangles), 
Trastuzumab-resistant JIMT-1 (circles) cells and ErbB2-negative A431 
(squares) cells, treated for 72 h with Erb–HP-RNase (empty symbols) or 
Erb–HP-DADD-RNase (black symbols). B: Quantitative analysis by 
western blotting of ErbB2-receptor levels on breast cancer (SKBR3 and 
JIMT-1) cell lines. The A431 cell line from human epidermoid carcinoma 
was used as a negative control. 
 
To test this hypothesis, an internalization assay was performed by 
using SKBR3 cells expressing high levels of ErbB2 and JIMT-1 cells 
expressing low levels of the receptor, as described in the “Materials and 
Methods” section. Briefly, cells were incubated for 2 h at 37°C with Erb–
HP-DDADD-RNase or the parental Erb–HP-RNase, washed with low pH 
stripping buffer to remove the protein bound to the cell surface, lysed and 
analyzed by western blotting by using a rabbit anti-HP-RNase antibody, 
followed by a HRP-conjugated anti-rabbit antibody. The results are 
shown in Figure 9: the presence of a reactive band corresponding to the 
expected molecular weight of the immunoRNase (46 kDa) in both the 
lysates shows that Erb–HP-DDADD-RNase is internalized by ErbB2-
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positive cells, and its levels are comparable to those of the native 
immunoRNase. Still, as expected, the levels of both internalized 
immunoRNases in SKBR3 cells are higher than those detected in JIMT-1 
cells (79). 
This result is in line with the hypothesis that higher levels of ErbB2 
in SKBR3 cells allow for the internalization of the immunoRNases at 
higher levels than those detected in resistant JIMT-1 cells expressing 
lower levels of ErbB2. 
Fig. 9 - Internalization of immunoRNases into tumor cells expressing 
different levels of ErbB2. Analysis by Western blotting of lysates from 
SKBR3 cells, expressing high levels of ErbB2, or JIMT-1 cells 
expressing low levels of ErbB2, untreated (control) or treated with Erb–
HP-RNase or Erb–HP-DDADD-RNase. 
 
1.2.  In vivo antitumor activity of Erb-HP-DDADD-RNase 
To evaluate the in vivo antitumor effects of Erb–HP-DDADD-
RNase, ErbB2-positive JIMT-1 cells, clinically resistant to Trastuzumab, 
were injected subcutaneously into Balb/cAnNCrlBR athymic (nu/nu) 
mice for in vivo studies. In order to compare the in vivo antitumor efficacy 
of this novel IR with that of the parental Erb-HP-RNase, the effects of 
equimolar doses of Erb-HP-RNase were tested in parallel on the same 
experimental model.  
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As shown in Figure 10, the treatment of mice bearing JIMT-1 
tumors with 5 doses, at 72 h intervals, of 1.2 mg kg
–1
 of Erb–HP-
DDADD-RNase significantly reduces tumor volume with respect to 
control mice treated with a PBS solution, whereas Erb–HP-RNase has a 
lesser antitumor effect. 
Thus, we can conclude that Erb–HP-DDADD-RNase exerts specific 
antitumor activity in vivo that is stronger than that of the parental 
immunoRNase, consistent with its resistance to RI (79).  
During treatment, the mice did not show signs of wasting or other 
visible signs of toxicity, thus confirming the lack of side toxic effects for 
the immunoRNases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 - In vivo effects of Erb–HP-DDADD-RNase or Erb–HP-RNase 
on Trastuzumab-resistant JIMT-1 tumors induced in mice. Treated 
mice (n = 5) were injected with five doses (arrows; 1.2 mg kg
–1
 of body 
weight) of Erb–HP-RNase (empty circles) or Erb–HP-DDADD-RNase 
(black circles). Control mice (n = 5) were treated with sterile PBS 
(squares). 
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1.3.  In vitro effects of Erb–HP-DDADD-RNase on human cardiac 
cells 
Anti-ErbB2 antibodies such as Trastuzumab have been found to be 
cardiotoxic in a high percentage of cases. To evaluate the potential 
cardiotoxic effects of Erb–HP-DDADD-RNase, a first analysis was 
carried out in vitro on human fetal cardiomyocytes (CFH). Cells were 
incubated at 37°C for 72 h in the absence or presence of increasing 
concentrations (50–100 nM) of an immunoRNase, and then analyzed by 
MTT assay to evaluate cell viability. Doxorubicin, at a concentration of 
0.1 or 0.25 μM, was used as a positive control. As shown in Figure 11A, 
Erb–HP-RNase and Erb–HP-DDADD-RNase do not have cardiotoxic 
effects, whereas doxorubicin was toxic for cardiac cells, as expected (79). 
1.4.  In vivo cardiotoxic effects of Erb–HP-DDADD-RNase 
The cardiotoxic effects of Erb–HP-DDADD-RNase were also tested 
in vivo on a mouse model. Groups of five mice were treated with five 
doses of immunoRNase comparable to those used for testing its 
therapeutic effects. Ecocardiography measurements were performed on 
mouse hearts before and after treatment. As shown in Figure 11 (B and D) 
Erb–HP-DDADD-RNase did not alter LVEDD and LVESD dimensions 
so that FS and the EF, which can signal myocardial failure, were not 
affected. This result is in line with the results previously obtained for the 
parental immunoRNase, which (unlike Trastuzumab and Doxorubicin) 
did not show cardiotoxic effects (31).  
To further validate this finding, we evaluated as an index of 
myocardial deformation, the RS, which is an early and sensitive predictor 
of the onset of cardiac dysfunction. As shown in Figure 11C, RS was not 
reduced by the treatment with Erb–HP-DDADD-RNase compared with 
sham, thus confirming that this immunoRNase, unlike Trastuzumab (31), 
does not impair cardiac function (79). 
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Fig. 11 - Cardiotoxic effects of Erb–HP-DDADD-RNase in 
vitro and in vivo. (A) Effects of Erb–HP-DDADD-RNase on the viability 
of human fetal cardiomyocytes (HFC) in vitro. Cells were treated for 72 h 
with Erb–HP-DDADD-RNase (striped bars) or Erb–HP-RNase (grey 
bars) at concentrations of 50 and 100 nM, or treated with doxorubicin 
(black bars) at concentrations of 0.1 and 0.25 μM or untreated (negative 
control, white bars). (B–D) Effects of Erb–HP-DDADD-RNase on heart 
function in vivo. Relative FS, RS and EF are reported before and after the 
treatment of mice (n = 5) with Erb–HP-DDADD-RNase (5 doses of 1.2 
mg kg
–1
 of body weight over 7 days). 
 
 
2. A novel approach for triple-negative breast cancer (TNBC) therapy  
 
2.1.  Generation, expression and purification of the novel anti-
Nucleolin immunoRNase 4LB5-HP-RNase 
The chimeric construct encoding 4LB5-HP-RNase was obtained by 
fusing the cDNAs encoding the human pancreatic RNase (HP-RNase) and 
the anti-NCL scFv 4LB5, as follows: the cDNA encoding the RNase was 
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cloned into the T7 promoter-based E. coli expression vector (pET22b+) 
downstream to the sequence encoding 4LB5 scFv. A spacer was included 
between the two cDNAs to minimize the steric hindrance between the two 
moieties of the chimeric protein, as previously described (36). The 
recombinant plasmid was sequenced to confirm faithful cloning. The 
resulting construct has the scFv at the N-terminal end, followed by a 
spacer inserted between the antibody fragment and the ribonuclease 
which is at the C-terminal end, followed by a hexahistidine tag useful for 
detection and purification of the chimeric construct (see Figure 12A). 
For the expression, cultures of E.coli BL21 (DE3) transformed with 
the recombinant pET22b+ expression vector containing the cDNA of 
4LB5-HP-RNase, were grown in LB medium with ampicillin to an 
OD600 of 0.6, induced with IPTG and incubated at 25°C overnight by 
shaking. To verify whether the chimeric protein was expressed as a 
soluble protein in the periplasmic space, cells were harvested by 
centrifugation and resuspended in B-PER buffer to evaluate the protein 
expression both in the periplasmic extract and in the inclusion bodies by 
Western Blotting with an anti-His mAb. The recombinant protein was 
more abundant in the inclusion bodies, (data not shown) thus the chimeric 
construct was purified from the insoluble fraction of transformed 
BL21(DE3) bacterial cells. Briefly, the insoluble fraction was treated with 
7 M UREA and then precipitated with ammonium sulfate, as described in 
“Material and Methods”. The resulting pellet was resolubilized in 
TALON binding buffer in the presence of 4 M UREA and protease 
inhibitors and loaded on a cobalt-chelating resin to allow for the protein 
purification by Immobilized-Metal Affinity Cromatography.  
The protein, eluted in a high concentration imidazole buffer, was 
analyzed by SDS-PAGE followed by Coomassie staining. As shown in 
Figure 12B, a single band of the expected molecular size of about 46 kDa 
was detectable, thus indicating that the heterologous protein was 
successfully purified. By Western Blotting analyses with an anti-His 
antibody, a band of the expected size corresponding to the chimeric 
protein was visualized, thus confirming the immunoreactivity of the 
isolated protein (Figure 12C). The fusion protein was then tested for its 
enzymatic activity by a zymogram, developed by using yeast RNA as a 
substrate. As illustrated in Figure 12D, a single active band was detected, 
corresponding to the molecular weight of 4LB5-HP-RNase, thus 
indicating that the immunoRNase retains the enzymatic activity of native 
human pancreatic ribonuclease comparable to that of another 
immunoRNase, Erb-HP-RNase, previously described (28), used as 
positive control. 
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Fig. 12 - Schematic representation and biochemical analyses of 
purified 4LB5-HP-RNase. A: Schematic representation of the human 
anti-Nucleolin immunoRNase 4LB5-HP-RNase. VH and VL, the variable 
heavy and light chains of the anti-Nucleolin scFv; linker, the flexible 
oligopeptide conjugating VH and VL; spacer, the peptide connecting the 
scFv and RNase; HP-RNase, human pancreatic RNase. B: SDS-PAGE 
analysis followed by Coomassie staining of the samples eluted by IMAC. 
Lane 1, molecular weight standard; lane 2, flow through; lane 3 and 4, 
fractions eluted from the column. C: Western blotting analysis by using 
an anti-His antibody of the samples as in Lane 3 and 4, respectively. D: 
Zymogram of 4LB5-HP-RNase (Lane 8) using yeast RNA as a substrate; 
Lane 7, enzymatic activity of Erb-HP-RNase used as positive control of 
the native human pancreatic ribonuclease activity. 
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2.2.  Binding assays of 4LB5-HP-RNase to NCL  
Although NCL is predominantly localized in the nucleolus, a large 
number of reports have shown an enhanced expression of cytoplasmic 
and surface NCL in many different actively proliferating tumor cell types 
(40).  
The ability of the recombinant fusion protein 4LB5-HP-RNase to 
bind to NCL-positive cells was analyzed by ELISA assays performed on a 
panel of breast cancer cells, such as MDA-MB-231, MDA-MB-436, BT-
549 (triple negative breast cancer) and MCF7 cells (luminal epithelial 
breast cancer), expressing high levels of surface-NCL. In parallel assays 
normal-like MCF10a breast cells, expressing low levels of surface-NCL, 
were used as a negative control.  
As shown in Figure 13A, 4LB5-HP-RNase specifically binds to all 
NCL-positive cancer cell lines with an affinity comparable to that of the 
parental 4LB5 scFv, tested in a parallel assay, whereas no significant 
binding to normal-like breast cells was detected. To further measure the 
binding affinity of 4LB5-HP-RNase to NCL expressed on live cells, 
binding curves were performed on each cell line by using increasing 
concentrations (5-500 nM) of the purified immunoRNase. As shown in 
Figure 13B, 4LB5-HP-RNase efficiently binds to the surface of these 
cells with an apparent affinity in the nanomolar range (5-50 nM). 
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Fig. 13 - ELISA binding assays of 4LB5-HP-RNase to NCL on cancer 
cells. A: The binding of 4LB5-HP-RNase to NCL-positive MDA-MB-
231, MCF-7, BT-549 or MDA-MB-436 breast cancer cells or to NCL-
negative MCF10a normal-like breast cells was tested by incubating the 
chimeric protein (100 nM) with the cells; 4LB5 was tested at equimolar 
doses as a positive control in parallel assays. B: Binding curves of 4LB5-
HP-RNase to surface NCL-positive MDA-MB-231 (rhomboids), MCF-7 
(squares), BT-549 (triangles), MDA-MB-436 (circles) breast cancer cell 
lines performed by using increasing concentrations (5-500 nM) of the 
immunoRNase. All the experiments are representative of three 
independent experiments performed in triplicate. Mean + SD is reported. 
 
 
To confirm that the observed binding was due to the specific 
interaction between 4LB5 and NCL, the binding of 4LB5-HP-RNase to 
MDA-MB-231 cells was analyzed by ELISA assay before and after its 
pre-incubation with equimolar doses of NCL-RBD (RNA Binding 
Domain) recombinant protein, used as a bait for the initial identification 
of 4LB5 scFv (74). As shown in Figure 14A, the pre-incubation of 4LB5-
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HP-RNase with the NCL-RBD recombinant protein resulted in a 
significant reduction (over 50%) of 4LB5-HP-RNase binding to the cells 
with respect to that observed in the absence of the recombinant protein.  
Finally, to confirm the interaction between endogenous Nucleolin 
and 4LB5-HP-RNase, a pull-down assay was carried out. To this aim, 
total cell extracts of MDA-MB-231 cells were incubated in the presence 
of either 4LB5-HP-RNase or 4LB5 and loaded on a high-capacity Ni-
NTA resin to allow for the isolation of the protein complexes by His-tag 
binding of the chimeric construct, as described in “Material and 
Methods”. Briefly, the resin was washed with cell lysis buffer and the 
associated proteins were resolved by SDS-PAGE in denaturing 
conditions. Bound NCL trapped in immunocomplexes with 4LB5-HP-
RNase or 4LB5 was detected by immunoblotting by using a commercial 
available anti-NCL mAb as primary antibody. 
As shown in Figure 14B, immunoblotting by using an anti-His 
antibody confirmed similar pull-down of 4LB5-HP-RNase (46 kDa) or 
4LB5 (27 kDa) proteins. Immunoreactive bands of the expected 
molecular size corresponding to Nucleolin (100 kDa) were observed in 
total cell extracts following NCL pull-down by using either 4LB5-HP-
RNase or 4LB5 with comparable intensity, thus confirming that 4LB5-
HP-RNase specifically binds to Nucleolin in a similar manner to the 
parental 4LB5 scFv. 
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Fig. 14 - Binding specificity assays of 4LB5-HP-RNase to NCL.  
A: ELISA assay performed by testing 4LB5-HP-RNase (50 nM) on 
MDA-MB-231 breast cancer cells in the absence (black) or in the 
presence (white) of equimolar doses of NCL-RBD recombinant protein. 
All the experiments are representative of three independent experiments 
performed in triplicate. Mean + SD is reported. B: Pull-down assay 
performed on lysates of MDA-MB-231 cells.  Lane 1: untreated total cell 
extract; lane 2: Ni-NTA resin (negative control); lane 3 and 4: cell 
extracts incubated with 100 nM 4LB5 or 4LB5-HP-RNase, respectively 
and pulled-down by using Nickel resin. Anti-NCL antibody (upper panel) 
and anti-His antibody (lower panel) were used to visualize the effective 
pull-down of endogenous NCL in the presence of either 4LB5 or 4LB5-
HP-RNase. 
 
2.3 4LB5-HP-RNase is internalized in surface NCL-positive breast 
cancer cells 
 
We have previously demonstrated that, following interaction with 
NCL, 4LB5 is actively internalized into breast cancer cells (74). To verify 
whether it occurs also for 4LB5-HP-RNase, we performed internalization 
experiments using MDA-MB-231 TNBC cells. To this aim, 4LB5-HP-
RNase was in vitro labeled with Cy5 fluorescent dye and added to culture 
medium for 4 h at 37°C. As control, cells were also incubated with 4LB5-
Cy5 or with Cy5 alone, for background evaluation. Cells were extensively 
washed using PBS and culture medium was replaced with fresh medium 
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containing Hoechst for nuclear staining, and analyzed by confocal 
microscopy. As shown in Figure 15A, no Cy5 fluorescent signal was 
observed when the cells were incubated in the presence of unconjugated 
fluorescent dye. However, intracellular localization was observed for both 
4LB5-Cy5 (Figure 15B) and 4LB5-HP-RNase-Cy5 (Figure 15C). Tri-
dimensional images (z-stacks) were also acquired in order to confirm that 
the fluorescent signal was localized inside the cell and not on the cell 
surface (Figure 15D). 
Fig. 15 - 4LB5-HP-RNase is internalized in TNBC cells.  
A-C: MDA-MB-231 cells were cultured in the presence of Cy5 (A), 
4LB5-Cy5 (B) or 4LB5-HP-RNase-Cy5 (C) for 4 h. Labeled compounds 
not internalized were washed away and cells were incubated with Hoechst 
nuclear staining, and live cell images were acquired. For each 
experimental condition, Hoechst, Cy5, Transmitted Detector (TD) and 
merge is reported. D: 3D-reconstruction of 4LB5-HP-RNase localization. 
Z-stack of cells shown in Figure 4C is reported, to evaluate the 
intracellular localization of 4LB5-HP-RNase. 
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2.4 4LB5-HP-RNase affects cancer cell viability and proliferation in 
vitro 
Down-regulation of NCL by siRNA in human cells results in 
growth arrest and defective centrosome duplication and appears to affect 
the integrity of the mitotic spindle, indicating its role in cell cycle 
regulation and cytokinesis (81-83). Moreover, NCL inhibition by using 
anti-NCL aptamer AS1411 (41) or scFv 4LB5 (74) impairs breast cancer 
cell proliferation both in vitro and in vivo. Then we hypothesized that the 
novel anti-NCL immunoRNase could display enhanced inhibitory effects, 
combining the anti-neoplastic properties of both 4LB5 and HP-RNase 
following intracytoplasmic delivery.   
The ability of 4LB5–HP-RNase to display a specific cytotoxic 
effect on NCL-positive cells was assessed by incubating MDA-MB-231, 
MDA-MB-436, BT-549 or MCF7 breast cancer cells in the absence or in 
the presence of increasing concentrations of the protein (10-200 nM). 
After 72 h of incubation at 37°C, cell survival was measured by counting 
trypan blue-excluding cells.  
As shown in Figure 16, 4LB5–HP-RNase was found to selectively 
and significantly inhibit the cell viability of all the NCL-positive MDA-
MB-231, MDA-MB-436, BT-549 and MCF7-cell lines tested, in a dose-
dependent manner, with an IC50 of about 25 nM, 50 nM, 12,5 nM or 25 
nM, respectively, whereas only slight effects on NCL-negative MCF-10a 
(normal-like) breast control cells were observed at high concentrations. 
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Fig. 16 - In vitro effects of the immunoRNase on tumor cell survival. 
Dose-response curves of NCL-positive MDA-MB-231 (rhomboids), 
MCF-7 (black squares), BT-549 (triangles) and MDA-MB-436 (circles) 
breast cancer cells or –negative MCF10a (empty squares) normal-like 
breast cells treated for 72 h with increasing doses (10-100 nM) of 4LB5-
HP-RNase. All the experiments are representative of three independent 
experiments performed in triplicate. Mean + SD is reported 
 
 
To further confirm the antitumor effects of the new construct, we 
also tested the effects of 4LB5-HP-RNase on the proliferation of surface-
NCL positive MDA-MB-231, MDA-MB-436 and BT-749 breast cancer 
cells, by colony formation assays. To this aim, the cells were seeded at 
low density in individual wells of a standard 6-well plate, treated with or 
without 100 nM of 4LB5-HP-RNase for 72 h and grown for 10 days in 
normal serum-medium. Colonies were then visualized by crystal violet 
staining and counted.  
The results (Figure 17) indicate that the number of colonies in the 
sample treated with 4LB5-HP-RNase is much lower than that of negative 
control cells and significantly reduced with respect to cells treated with 
the parental 4LB5 scFv, tested in parallel assays, thus indicating that 
4LB5-HP-RNase inhibits the proliferation of all treated cells more 
efficiently than the parental scFv probably due to its acquired RNase 
activity. 
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Fig. 17 - In vitro effects of 4LB5-HP-RNase on cancer cell 
proliferation. Colony assays on triple-negative BT-549 (A), MDA-MB-
436 (B) and MDA-MB-231 (C) breast cancer cells performed in the 
absence or in the presence of 100 nM of 4LB5-HP-RNase or 4LB5, tested 
in parallel assays, and stained after 10 days with Crystal violet. All the 
experiments are representative of three independent experiments 
performed in triplicate. 
 
2.5  4LB5-HP-RNase induces apoptosis in surface NCL-positive 
cancer cells  
Several recent reports indicate that NCL is a negative regulator of 
cell apoptosis. The role of cell surface NCL is highlighted by studies 
showing that functional blockage or down-regulation of cell surface NCL 
expression inhibits migration and tube formation (84, 85), and causes 
endothelial-cell apoptosis (86).  
To investigate whether the reduction of the viability and 
proliferation observed for the surface-NCL cells treated with 4LB5-HP-
RNase was associated with its ability to induce apoptosis, the MDA-MB-
231 triple-negative breast cancer cells were treated with increasing 
concentrations of 4LB5-HP-RNase (1-200 nM). After 72 hours of 
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treatments, total cell extracts were analyzed by Western Blotting to 
measure the reduction of full-length poly(ADP-ribose) polymerase 
(PARP) levels, which is a pro-apoptotic signal (87).  
The results, shown in Figure 18, indicate that 4LB5-HP-RNase 
induces in treated cells PARP degradation in a dose-dependent manner 
with the total loss of the PARP-signal following the treatment with 50 nM 
protein concentration, thus confirming the activation of the apoptotic 
pathway by the anti-NCL immunoRNase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18 - Effects of 4LB5-HP-RNase on cancer cell apoptosis. A: Dose-
response curve of NCL-positive MDA-MB-231 cells (rhomboids) treated 
for 72h with increasing doses (10-200 nM) of 4LB5-HP-RNase. B: 
Western Blotting analysis of total lysates from MDA-MB-231 cells 
treated with increasing concentrations (10-200 nM) of 4LB5-HP-RNase 
to evaluate inactive-PARP cleavage. Actin was used as loading control.  
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2.6  Effects of 4LB5-HP-RNase on the levels of oncogenic 
intracellular and extracellular miRNAs 
The importance of NCL in cancer biology was recently highlighted 
by studies showing that NCL regulates the maturation and the expression 
of a specific subset of miRNAs, including miR-21, miR-221, miR-222, 
that are causally involved in breast cancer initiation, progression, and 
drug resistance (41, 88-91).  
In order to assess if the chimeric 4LB5-HP-RNase protein affects 
the levels of these miRNAs, triple-negative MDA-MB-231 breast cancer 
cells were treated with increasing doses of 4LB5-HP-RNase and the RNA 
was extracted after 72 hours of treatment. As shown in Figure 19A, the 
Real-Time PCR analysis reveals that the levels of the mature forms of 
miR-21, miR-221 and miR-222 are strongly reduced in a dose-dependent 
manner by the treatment with 4LB5-HP-RNase with a relevant effect 
already detectable at the lowest concentration tested for all the miRNAs 
analyzed. 
Previous studies have demonstrated that 4LB5 was already able to inhibit 
the interaction between NCL and the micro-RNA microprocessor 
complex impairing the maturation of these NCL-dependent miRNAs (74). 
To evaluate if 4LB5-HP-RNase-associated effects on mature 
miRNAs levels were due also to the effective RNA degradation action of 
the ribonuclease moiety and not only to the inhibition of the interaction 
between NCL and microprocessor complex by the scFv domain, MDA-
MB-231 cells were treated in parallel assays with equimolar doses of 
4LB5 or 4LB5-HP-RNase. As shown in Figure 19B, the immunoRNase 
impairs the miRNAs levels more efficiently than 4LB5, thus suggesting 
that the enzymatic activity of the ribonuclease strongly enhances the 
action of 4LB5 on miRNAs levels.  
These results demonstrate that 4LB5-HP-RNase efficiently impairs 
the levels of miRNAs extensively associated with an invasive phenotype 
of breast cancer cells resistant to the conventional anti-cancer therapies, 
and that this effect is due also to its enzymatic activity. 
Since cancer cells actively release extracellular vescicles (EVs) into 
surrounding tissues which play pleiotropic roles in cancer progression, 
such as immune escape, neovascularization and metastatis, we also tested 
the effects of 4LB5-HP-RNase on their EV-packed miRNas. Particularly, 
oncogenic miR-21, miR-221 and miR-222 were previously demonstrated 
to be released by colon cancer cells and transferred to other cancer cells, 
mediating their aggressiveness (92). 
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Fig. 19 - Effects of 4LB5-HP-RNase on miRNAs levels in cancer cells. 
A: NCL-dependent mature miR-21, -221 and -222 levels were analyzed 
by real-time PCR after 72 h of incubation of MDA-MB-231 cells with 
increasing concentrations (6-100 nM) of 4LB5-HP-RNase. B: 
Comparison between the effects of 4LB5 (grey bars) and 4LB5-HP-
RNase (white bars) on mature miR-21, -221 and -222 levels by using an 
intermediate concentration (25 nM) of chimeric proteins for the treatment 
of MDA-MB-231 cells. Relative microRNA expression levels were 
normalized for control untreated sample, and relative abundance (fold 
change) is reported. Data are the average of three independent 
experiments performed in triplicate. Mean + SD is reported. 
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In order to investigate the hypothesis that NCL may display a 
protective role on cancer cell-derived EVs-associated miRNAs, we have 
tested for the first time the ability of both anti-NCL 4LB5-HP-RNase and 
4LB5 scFv to affect the levels of EVs-related miR-21 following the 
binding and the possible displacement of the Nucleolin from the miR. To 
this aim we have initially isolated the EVs from the conditioned serum-
deprived medium of lymph node metastatic derivatives colorectal SW620 
cancer cells which are widely used in literature as model for exosomes 
studies (93). Then, using a combination of a polymer-based exosome 
precipitation and a differential centrifugation approach to fractionate the 
EVs-containing medium, we have isolated the SW620-derived exosomes 
which were tested for the presence of NCL by western blotting analysis 
(data not shown). Once confirmed the presence of NCL, EVs were then 
treated with either 4LB5-HP-RNase or 4LB5 scFv at a concentration of 
50 nM for 2 hours at 37°C. The total RNA was extracted and the 
exosomes-related miR-21 levels were analyzed by Real-Time PCR 
analysis. RNU48 snoRNA was used as negative control to evaluate the 
potential contamination of cellular RNAs during the EVs purification 
procedure.  
As shown in Figure 20, 4LB5-HP-RNase strongly reduces the miR-
21 levels with respect to the untreated control, whereas the treatment with 
an equimolar dose of 4LB5, tested in a parallel assay, only slightly affects 
the miR-21 levels.  
These data support the hypothesis that the binding of Nucleolin by 
the scFv 4LB5 may cause the displacement of the Nucleolin from the 
miR-21 allowing for the RNase moiety present in 4LB5-HP-RNase to 
degrade miR-21. Thus, the enzymatic activity of 4LB5-HP-RNase could 
be responsible for its more potent antitumor effects on extracellular 
miRNAs, thus indicating a potential role of the anti-NCL immunoRNase 
in the inhibition of cancer cell-cell communication involved in the tumor 
progression. 
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Fig. 20 - Effects of 4LB5-HP-RNase on cancer cells-derived 
extracellular vescicles-miR-21. The mature miR-21 levels were 
analyzed by real-time PCR on RNA extracted from exosomes derived 
from the conditioned medium of SW620 cancer cells treated for 72 h with 
equimolar doses (50 nM) of 4LB5-HP-RNase (white bars) or 4LB5 (grey 
bars), tested in a parallel assay. Relative microRNA expression levels 
were normalized for control untreated sample, and relative abundance 
(fold change) is reported. The snoRNA RNU48 was used as negative 
control of RNAs cellular contamination.  
 
2.7  In vivo effects of 4LB5-HP-RNase 
 
To evaluate the therapeutic effects of 4LB5-HP-RNase in vivo, we 
generated orthotopic mouse models of human TNBC by injecting surface-
NCL positive MDA-MB-231 triple-negative breast cancer cells into the 
mammary fat pad of Non Obese Diabetic-Severe Combined 
ImmunoDeficient (NOD-SCID) mice. Two weeks after the injection, 
groups of five mice bearing tumors of comparable size received 
intraperitoneal injection of PBS solution or 2 mg/kg 4LB5-HP-RNase, 
twice weekly. As shown in Figure 21A, four weeks after the first 
treatment, 4LB5-HP-RNase strongly reduced tumor volume in 
comparison with those of control mice, thus indicating that it exerts 
specific antitumor activity in vivo.  
In order to compare the in vivo antitumor effects of 4LB5-HP-
RNase with those observed for the parental 4LB5 scFv (74), a second in 
vivo experiment was performed in the same experimental model. Mice 
bearing tumors of comparable reduced sizes were injected with equimolar 
doses of 4LB5 or 4LB5-HP-RNase in order to compare their efficacy. As 
shown in Figure 21B, compared with 4LB5, 4LB5-HP-RNase shows a 
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stronger antitumor activity even though its larger size could reduce its 
diffusion into the tumors with respect to the parental scFv. Interestingly, 
H&E staining (Figure 21C, upper panel) shows reduced cellularity and 
several areas of necrosis following treatment with the 4LB5-HP-RNase. 
In addition, Ki-67 staining of treated tumors indicates a reduced 
proliferation rate compared with controls (Figure 21C, lower panel). 
During all the treatments, mice did not show signs of wasting, such as 
loss of weight (Figure 21D) or other visible signs of toxicity, thus 
suggesting that 4LB5-HP-RNase was not toxic for normal tissues. 
Fig. 21 - A: In vivo effects of 4LB5-HP-RNase on NCL-positive 
tumors induced in mice by using MDA-MB-231 breast cancer cells. 
A: NOD-SCID (n = 5) mice were injected with 2 × 10
6
 MDA-MB-231-
Luc cells into the mammary fat pad. After 2 weeks, mice were treated 
with control PBS solution or 2 mg/kg of 4LB5-HP-RNase twice a week. 
Mice were monitored by IVIS weekly. At 6 weeks from injection (4 
weeks of treatment), mice were sacrificed. Tumors were excised and 
measured. B: In a second experiment, mice were treated with equimolar 
doses of 4LB5 or 4LB5-HP-RNase (2 mg/kg) or with PBS, as described 
for Figure 21A. C: Representative images of H&E and Ki-67 staining of 
tumors shown in B; 20x magnification is reported. D: Weight of mice 
treated with PBS (black bars), 4LB5 (grey bars) or 4LB5-HP-RNase 
(white bars). 
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DISCUSSION 
 
This study aims at the identification of innovative approaches for BC 
therapies based on the generation and characterization of two 
immunoRNAses: 
 
1. Breast cancer: novel ErbB2-targeted therapies 
 
ErbB2 amplification is an early event in the development of breast 
cancer (94, 95) and ErbB2 overexpression is associated with a poor 
prognosis (6), as the receptor plays a key role in tumor cell growth. 
Indeed, ErbB2 overexpression on the surface of tumour cells induces the 
formation of ErbB heterodimers and homodimers, thus leading to an 
excess of ErbB-mediated signalling, which drives oncogenic cell survival 
and proliferation (17-19). 
Its oncogenic potential, its selective overexpression in human 
tumors and its accessibility on tumor cell surface make ErbB2 a good 
target for the development of new anticancer agents, including 
monoclonal antibodies that target the extracellular domain of the receptor. 
The humanized anti-ErbB2 antibody Trastuzumab is widely used 
for the therapy of breast cancer with some success. However, a high 
percentage of breast cancer patients are resistant to Trastuzumab 
treatment and/or manifest adverse side effects, such as cardiac 
dysfunction (11-15), due to the inhibition in cardiac cells of ErbB2 
signalling pathway, which is known to play a key role in survival pathway 
of cardiomyocytes (16).  
Pertuzumab, another humanized anti-ErbB2 antibody recently 
approved by the FDA for metastatic breast cancer therapy, has shown a 
limited efficacy in clinical trials. Furthermore, it has been found to induce 
cardiac dysfunction, although it was not possible to assess whether the 
rate is similar to that of Trastuzumab. In fact, the limited number of small 
clinical trials on patients that have already supported Trastuzumab 
therapy without cardiotoxic effects, provide us with partial and 
preliminary results (11).  
A different approach with respect to ‘naked’ antibodies targeting 
ErbB2 is the use of antibody–drug conjugates. Recently, Trastuzumab has 
been conjugated to a maytansine derivative (DM1), a potent 
antimicrotubule agent, leading to the approval of the new drug, called T-
DM1 (8). After the binding to ErbB2, T–DM1 is internalized and DM1 is 
subsequently released into the cell, thus delivering the chemotherapeutic 
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agent directly into the cells that overexpress ErbB2 (96). Although T–
DM1 has shown encouraging anti-tumor effects in preclinical and early 
clinical studies (8, 97), it recognizes the same epitope of ErbB2. For this 
reason, it should have the same limitations of Trastuzumab, such as the 
same effects on signaling pathways in cardiac cells and a similar inability 
to recognize resistant cells expressing ErbB2 variant, such as Delta16 
(lacking the exon 16) (98), or those cells expressing mucins, such as 
MUC4 or other receptors, that mask the Trastuzumab epitope (30). 
In our laboratory a novel fully human antibody fragment was 
obtained by phage display: it recognizes an epitope of ErbB2 different 
from that of Trastuzumab and Pertuzumab and consequently has a 
different mechanism of action. In particular, it does not show toxic effects 
on cardiac cells and it is able to inhibit some Trastuzumab resistant tumor 
cell lines (99). 
Furthermore, in order to overcome the limits of toxins, novel fully 
human immunoconjugates, such as immunoRNases, have been generated 
in our laboratory by fusing the human anti-ErbB2 scFv, named Erbicin, 
with human non immunogenic ribonucleases (RNases), that can 
specifically degrade cellular RNAs and induce tumor cell death once 
internalized through antibody mediated endocytosis.  
In this project of thesis, we have characterized Erb–HP-DDADD-
RNase, a fully human inhibitor-resistant immunoRNase targeting the 
ErbB2 receptor. This immunoRNase was obtained by fusing a variant of 
human pancreatic RNase (HP-DDADD-RNase), made resistant to RI, 
with Erbicin, the novel anti-ErbB2 scFv (36, 99).  
The novel immunoRNase retains the biological actions of both 
antibody and RNase moieties. It binds to a panel of ErbB2-positive breast 
cancer cells expressing different levels of ErbB2 with an affinity 
comparable to that of the parental scFv, it has an enzymatic activity 
similar to that of the previously reported immunoRNase Erb–HP-RNase 
(28), but inhibits the growth of breast cancer cells more efficiently due to 
its resistance to RI (36). 
In this study, we demonstrate that the differential efficacy of the 
two immunoRNases is highlighted on cell lines expressing low levels of 
ErbB2 receptor. Indeed, less efficient internalization of the 
immunoRNases into the cytosol does not affect the cytotoxicity of the 
novel immunoRNase Erb–HP-DDADD-RNase, but leads to full 
inhibition of the parental Erb–HP-RNase. In addition, Erb–HP-DDADD-
RNase inhibits the growth of Trastuzumab-resistant breast cancer cells in 
vitro and in vivo with a greater potency than that of the parental 
immunoRNase. Finally, in line with the results previously obtained for 
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the parental immunoRNase (31), Erb–HP-DDADD-RNase does not show 
cardiotoxic effects either in vitro on human cardiomyocytes or in vivo on 
a mouse model (79).  
Thus, Erb–HP-DDADD-RNase could be a promising candidate for 
those patients ineligible for Trastuzumab treatment due to primary or 
acquired Trastuzumab resistance or due to cardiac dysfunction. 
 
2. A novel approach for triple-negative breast cancer (TNBC) 
therapy  
 
ErbB2 overexpression has been reported in only 25% of human 
breast cancers (4), whereas most of them are ErbB2-negative, such as 
triple negative tumors (TNBC). TNBC is characterized by the absence of 
estrogen receptor (ER), progesterone receptor (PR) and ErbB2, thus 
representing a unique subgroup, with a specific molecular profile, lack of 
effective therapies and aggressive behavior with consequent poor 
prognosis. 
Contrary to other breast cancer subtypes, for which therapies 
targeting biological drivers of tumorigenesis proved to be successful, no 
molecular targeted agent is approved for TNBC yet. Thus, it is imperative 
to develop new strategies able to control TNBC and delay the onset of 
patient’s resistant to chemotherapy. 
A new target for immunotherapy of TNBC could be represented by 
Nucleolin (NCL). NCL is a highly conserved nucleocytoplasmic 
multifunctional protein, localized in the nucleolus, nucleus and cytoplasm 
of the cell which participates in many cellular functions under both 
physiological and pathological conditions. Recent reports show that NCL 
is frequently up-regulated and selectively expressed on the surface of 
cancer cells and cancer associated endothelial cells but not on their 
normal counterparts. Following the interaction with various ligands, 
surface Nucleolin is implicated directly or indirectly in signal 
transduction events (70) and plays a critical role in tumorigenesis, tumor 
invasiveness, inflammation and/or angiogenesis. 
NCL is also a major component of the ribosomal RNA nucleolar-
processing complex (40, 100) and it is directly involved in miRNA 
biogenesis (101), including that of miR-10a, miR-21, miR-103, miR-221, 
and miR-222. Since the miR-21, miR-221 and miR-222 up-regulation has 
been associated with breast cancer aggressiveness and resistance to 
antineoplastic therapies (59-62), NCL has a critical protumorigenic 
function by regulating their biogenesis at the post transcriptional level, 
thus enhancing their maturation from pri- to pre-miRNAs (41). 
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Interestingly, miRNAs can also be detected in extracellular 
compartments (102-105) where they are stably “protected” as they can 
either be associated with RNA-binding proteins and lipoprotein 
complexes or they can be packaged into extracellular vescicles (EVs) 
(105, 106). Furthermore, some studies support a shift of miRNAs from 
the protein bound to the exosomal compartment (and vice versa) (65), 
highlighting a novel mechanism of intercellular communication in which 
RNA-binding proteins, such as NCL, may be associated in complexes for 
the packaging and export of these miRNAs, thus protecting them from 
proteases degradation. 
Altogether, these data provide evidence that Nucleolin is a 
promising target for cancer therapy. Indeed, given the continuous and 
abundant expression in tumor compared to normal cells, tumor cells are 
the preferential targets of inhibitors of surface Nucleolin without affecting 
nuclear Nucleolin of normal cells (40). To this aim a number of molecules 
that target cell surface NCL are being developed as potential anti-cancer 
therapeutics, such as peptides (HB-19 pseudopeptide or structurally 
related Nucant pseudopeptides) or aptamers (AS1411). Although 
promising, they have intrinsic limitations, such as extremely short half-
life or undesired immunostimulatory actions that may be a concern if 
these drugs are used for breast cancer therapy (73). 
To overcome these limits, we previously selected by phage-display 
technology a fully human recombinant anti-NCL scFv, named 4LB5, 
which specifically binds to NCL on the cell surface of cancer cells. This 
scFv displayed a significant ability to discriminate between cancer and 
normal-like breast cells to selectively reduce tumor cell viability, 
proliferation, and migration, and induce apoptosis in cancer cells. 
Furthermore, 4LB5 treatment affects the expression of mature miR-21, -
221, and -222, by interfering in the NCL interaction with DGCR8 and 
impairing the maturation of the primary forms of these miRNAs (74).  
Based on the ability of 4LB5 to translocate into the cytoplasm 
following NCL binding, this scFv can be used to vehicle antitumoral 
molecules directly into cancer cells thus enhancing its therapeutic 
activity. To this aim, we engineered a novel anti-NCL immunoRNase, 
named 4LB5-HP-RNase, by fusing the human scFv moiety with the 
human pancreatic RNase (HP-RNase), thus combining per se antitumoral 
activity of 4LB5 with the enzymatic activity of the ribonuclease, which 
can be useful to degrade NCL associated miRNAs or intracellular RNAs. 
Indeed, the novelty of this study has been to combine two activities for 
selective cancer cell death that, to our knowledge, has never been 
described for TNBC and appear to be highly promising for its therapy. 
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Here we describe the construction, characterization and antitumor 
activity of the novel NCL-targeting immunoRNase. We demonstrate that 
4LB5-HP-RNase retains the biological action of both the antibody and 
RNase moieties. In fact, the novel immunoRNase selectively and 
efficiently binds to a panel of different surface-NCL positive breast 
cancer cells but not to normal-like breast cancer, and shows an enzymatic 
activity comparable to that of the previously characterized IR (Erb-HP-
RNase) (28). Moreover, 4LB5-HP-RNase treatment of breast cancer cells, 
but not of normal-like breast cells, significantly reduces their in vitro and 
in vivo growth by inducing apoptosis. 
Interestingly, 4LB5-HP-RNase strongly affects the intracellular 
levels of tumorigenic miR-21, -221, and -222 in breast cancer cells, in a 
more potent manner with respect to that of 4LB5, thus indicating that the 
acquired enzymatic activity improves the antitumoral efficacy of 4LB5. 
Finally, we report on preliminary critical data suggesting a key role 
of NCL in EVs-mediated cancer intracellular communication. Here we 
show that NCL is present in the exosomes released from cancer cells and 
that the treatment with the anti-NCL IR strongly reduces EVs-associated 
miR-21 levels. These data strongly support the hypothesis that NCL may 
be directly involved in EVs-mediated intracellular communication and 
that molecules targeting NCL might represent a new important approach 
to impair it. However, further studies will have to be carried out to 
investigate the traffic of both NCL and miRNAs in EVs and their 
molecular association.  
In summary, here we describe a new approach for immunotherapy 
of TNBC based on a novel fully human NCL-targeting immunoconjugate 
with potent antineoplastic activity that could be useful for the treatment of 
different types of carcinoma, ineligible to Trastuzumab treatment or to 
other currently available targeted therapies. 
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